http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#Head http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#assertion http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#provenance http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#pubinfo http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#assertion http://purl.obolibrary.org/obo/DOID_8577 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_8577 http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00860 http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association http://www.w3.org/2000/01/rdf-schema#label prednisolone sodium phosphate oral solution 15 mg prednisolone per 5 ml is indicated in the following conditions 1 allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with seasonal or perennial allergic rhinitis asthma contact dermatitis atopic dermatitis serum sickness drug hypersensitivity reactions 2 dermatologic diseases pemphigus bullous dermatitis herpetiformis severe erythema multiforme stevens johnson syndrome exfoliative erythroderma mycosis fungoides 3 edematous states to induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations with idiopathic nephrotic syndrome without uremia 4 endocrine disorders primary or secondary adrenocortical insufficiency hydrocortisone or cortisone is the first choice synthetic analogs may be used in conjunction with mineralocorticoids where applicable in infancy mineralocorticoid supplementation is of particular importance congenital adrenal hyperplasia hypercalcemia associated with cancer nonsuppurative thyroiditis 5 gastrointestinal diseases to tide the patient over a critical period of the disease in ulcerative colitis regional enteritis 6 hematologic disorders idiopathic thrombocytopenic purpura in adults selected cases of secondary thrombocytopenia acquired autoimmune hemolytic anemia pure red cell aplasia diamond blackfan anemia 7 neoplastic diseases for the treatment of acute leukemia and aggressive lymphomas in adults and children 8 nervous system acute exacerbations of multiple sclerosis 9 ophthalmic diseases uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids temporal arteritis sympathetic ophthalmia 1 respiratory diseases symptomatic sarcoidosis idiopathic eosinophilic pneumonias fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy asthma as distinct from allergic asthma listed above under allergic states hypersensitivity pneumonitis idiopathic pulmonary fibrosis acute exacerbations of chronic obstructive pulmonary disease copd and pneumocystis carinii pneumonia pcp associated with hypoxemia occurring in an hiv individual who is also under treatment with appropriate anti pcp antibiotics studies support the efficacy of systemic corticosteroids for the treatment of these conditions allergic bronchopulmonary aspergillosis idiopathic bronchiolitis obliterans with organizing pneumonia 11 rheumatic disorders as adjunctive therapy for short term administration to tide the patient over an acute episode or exacerbation in psoriatic arthritis rheumatoid arthritis including juvenile rheumatoid arthritis selected cases may require low dose maintenance therapy ankylosing spondylitis acute and subacute bursitis acute nonspecific tenosynovitis acute gouty arthritis epicondylitis for the treatment of systemic lupus erythematosus dermatomyositis polymyositis polymyalgia rheumatica sjogren s syndrome relapsing polychondritis and certain cases of vasculitis 12 miscellaneous tuberculous meningitis with subarachnoid block or impending block tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty and tuberculosis with pleural or pericardial effusion appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications trichinosis with neurologic or myocardial involvement acute or chronic solid organ rejection with or without other agents http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00860 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#provenance http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#pubinfo http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#sig http://purl.org/nanopub/x/hasSignature e1XtjtqRrY+QLzLROpID8CYBTf70jQdBd7sSD5kuGfU/mlRx1OdnwvSDzMPENx9jQS/EAJwvii/HpGTXp+JSLWihhpMd+UBTG6Sf8OgcL+SsHUgdDjCJ5rfjlv3R93nVJtgEPYIOC9vaD6vtG2wuGj3gCOIHBHTLOLak3Ph/ZIY= http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://purl.org/dc/terms/created 2021-06-12T16:22:43.726+02:00 http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAZxpzYbymcxVqn0Pgp6SwrSV0F-LmwIDxtx4JBG3ee6c https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs